Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The prevalence of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in Brazil and Mexico is estimated at 1.3 million and is expected to keep growing. The entry of biosimilars and the upcoming arrival of novel therapies for PsA and AS are shaping a new therapeutic landscape in Brazil and Mexico, which is currently dominated by the long established TNF-alfa inhibitors. In this Access & Reimbursement analysis, we discuss the current access landscape to PsA and AS treatments in Brazil and Mexico and the expected future uptake of biosimilars and key emerging therapies (e.g., Novartis’s Cosentyx, Janssen’s Stelara, Celgene’s Otezla)— and the levers and roadblocks to their uptake—based on primary research with rheumatologists and payers in these two countries.
Questions Answered in This Report:
For this Access & Reimbursement module on PsA and AS, we surveyed 105 rheumatologists and interviewed 6 payers to explore the current and future dynamics in the use and coverage of premium-priced PsA and AS therapies in Brazil and Mexico. Interviewees have regional or national influence or inform regulations on AS and PsA.
Markets covered: Brazil, Mexico.
Already a Client? Log in to access this report.